期刊
INTERNAL MEDICINE
卷 56, 期 14, 页码 1825-1829出版社
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.56.8040
关键词
gastric hyperplastic polyp; Helicobacter pylori; proton pump inhibitor; gastrin receptor; gastrin
资金
- Chugai Pharmaceutical Co., Ltd.
- Bristol-Myers Squibb
- Eisai Co., Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- AstraZeneca K. K.
- Astellas Pharma Inc.
A 56-year-old man with gastroesophageal reflux disease (GERD) was referred to our hospital. Esophagogastroduodenoscopy (EGD) revealed no evidence of any polypoid lesions in the stomach, and the patient had no history of Helicobacter pylori infection. He received omeprazole (20 mg) once daily for the GERD. EGD was performed at 1 year after the start of omeprazole administration, and this time, gastric hyperplastic polyps (GHPs) were detected. The GHPs increased in size as the omeprazole treatment continued, but they markedly decreased in size following omeprazole discontinuation. Thus, the administration of proton pump inhibitors may be a risk factor for the development of GHP independent of H. pylori infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据